Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Morgan Stanley Initiates Coverage On Silence Therapeutics with Equal-Weight Rating, Announces Price Target of $18

Author: Benzinga Newsdesk | December 09, 2022 08:26am
Morgan Stanley analyst Andrew Galler initiates coverage on Silence Therapeutics (NASDAQ:SLN) with a Equal-Weight rating and announces Price Target of $18.

Posted In: SLN

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist